Texas Institute for Genomic Medicine Will Supply Myelin Repair Foundation with Knockout Research Mice Throughout North ... Business Wire via Yahoo! Finance Wed, 04 Apr 2007 9:00 AM PDT HOUSTON----The Texas Institute for Genomic Medicine has entered into an agreement with the Myelin Repair Foundation to supply up to 15 pair of genetically altered mice over the next 12 months for collaborative research in the U.S. and Canada to find the cause and possible treatments for multiple sclerosis .

Opexa reports positive MS vaccine data Pharmaceutical Business Review Tue, 03 Apr 2007 6:27 PM PDT Opexa Therapeutics has reported positive data in a phase I/II dose escalation clinical trial of the investigational T-cell vaccine, Tovaxin, for multiple sclerosis.

The Immune Response Corporation Announces Rebranding to Reflect Expanded Focus on Treatment of Autoimmune Diseases
RedNova Wed, 04 Apr 2007 5:00 AM PDT
CARLSBAD, Calif., April 4 /PRNewswire-FirstCall/ -- The Immune Response Corporation (BULLETIN BOARD: IMRP) announced today that effective April 16 the company will be known as Orchestra Therapeutics, Inc.